ARS Pharmaceuticals, Inc. Common Stock (SPRY) Stock Price

SPRYStock

$4.02−60.24%52W

Market Cap$399.78M

P/E102.30x

PEG Ratio—

Div yield—

Beta0.92

SPRY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-60.52%

Price vs S&P 500 (4W)-6.26%

VGM Score43.78

P/E Ratio (Annual)102.30x

P/CF (Annual)60.39x

Book Value / Share (Quarterly)$0.13

P/TBV (Annual)11.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)299.68%

Cash Flow / Share (Quarterly)$-1.98

Price vs S&P 500 (YTD)-77.42%

Gross Margin (TTM)71.37%

Net Profit Margin (TTM)-184.24%

EPS (TTM)$-2.17

10-Day Avg Trading Volume1.61M

EPS Excl Extra (TTM)$-2.17

EPS (Annual)$-1.74

ROI (Annual)-81.33%

Gross Margin (Annual)76.72%

Cash / Share (Quarterly)$1.45

Revenue Growth QoQ (YoY)114.15%

P/E Normalized (Annual)102.30x

ROA (Last FY)-52.28%

Revenue Growth TTM (YoY)4.08%

EBITD / Share (TTM)$-2.17

ROE (5Y Avg)-42.32%

Operating Margin (TTM)-184.96%

Cash Flow / Share (Annual)$-1.72

P/B Ratio31.95x

P/B Ratio (Quarterly)63.57x

Net Income / Employee (Annual)$-1,084,200

EV / Revenue (TTM)4.18x

Net Interest Coverage (TTM)-64.94x

ROA (TTM)-69.63%

EV / EBITDA (TTM)102.89x

EPS Incl Extra (Annual)$-1.74

Current Ratio (Annual)7.28x

Quick Ratio (Quarterly)3.13x

3-Month Avg Trading Volume1.87M

52-Week Price Return-60.24%

EV / Free Cash Flow (Annual)65.84x

Revenue / Employee (TTM)$740,000

Tangible BV / Share (Quarterly)$0.47

P/S Ratio (Annual)4.74x

Asset Turnover (Annual)0.26x

52-Week High$13.15

EPS Excl Extra (Annual)$-1.74

CapEx CAGR (5Y)-18.10%

26-Week Price Return-50.61%

Quick Ratio (Annual)6.91x

13-Week Price Return-42.57%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)3.48x

Enterprise Value$488.29M

Asset Turnover (TTM)0.38x

Revenue / Employee (Annual)$533,400

Pretax Margin (Annual)-203.35%

Cash / Share (Annual)$2.47

3-Month Return Std Dev71.58%

Net Income / Employee (TTM)$-1,363,500

ROE (Last FY)-149.92%

Net Interest Coverage (Annual)-20.86x

EPS Basic Excl Extra (Annual)$-1.74

Receivables Turnover (TTM)3.25x

Total Debt / Equity (Quarterly)7.73x

EPS Incl Extra (TTM)$-2.17

ROI (TTM)-119.43%

P/S Ratio (TTM)3.42x

Revenue / Share (Annual)$0.85

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-75.77%

Year-to-Date Return-65.49%

5-Day Price Return-3.83%

EPS Normalized (Annual)$-1.74

ROA (5Y Avg)-22.49%

Net Profit Margin (Annual)-203.25%

Month-to-Date Return-6.73%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-1.81

Operating Margin (Annual)-212.92%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-28.60%

LT Debt / Equity (Quarterly)7.73x

EPS Basic Excl Extra (TTM)$-2.17

P/TBV (Quarterly)16.92x

P/B Ratio (Annual)10.08x

Inventory Turnover (TTM)3.28x

Pretax Margin (TTM)-184.31%

Book Value / Share (Annual)$1.15

Price vs S&P 500 (13W)-45.26%

Beta0.92x

P/FCF (Annual)30.79x

Revenue / Share (TTM)$1.18

ROE (TTM)-256.67%

52-Week Low$3.81

vGradeD

gGradeB

mGradeD

vgmGradeC

SPRY Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.49	-$0.63	-27.70%(-$0.14)
Q1 2026	May 15, 2026	-$0.54	-$0.61	-14.02%(-$0.07)
Q4 2025	Mar 9, 2026	-$0.48	-$0.42	+12.50%(+$0.06)
Q3 2025	Nov 10, 2025	-$0.49	-$0.52	-6.12%(-$0.03)
Q2 2025	Aug 13, 2025	-$0.52	-$0.46	+10.68%(+$0.05)

SPRY Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.36

4.40

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SPRYARS Pharmaceuticals, Inc. Common Stock	D	B	D	3.4x	4.1%	71.4%	—	$4.02
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About ARS Pharmaceuticals, Inc. Common Stock

ARS Pharmaceuticals commercializes Neffy, a needle-free intranasal epinephrine treatment for Type 1 allergic reactions and anaphylaxis. The proprietary formulation combines epinephrine with an absorption enhancer to deliver efficacy comparable to injectable alternatives. Neffy is marketed globally under different trade names, including EURneffy in the European Union and United Kingdom.